Which is better, thymosin alpha-1 or TB-500?
Thymosin alpha-1 wins on evidence grade (human RCT versus animal only) and on regulatory standing internationally, as an approved drug in more than 30 countries with a benign safety record across decades of trials. TB-500 has no human data: the randomized eye drop trial in dry eye, where both primary endpoints missed, used full-length thymosin beta-4, which FDA says is not the same substance as TB-500, and the identity of injectable products sold as TB-500 is not verified. In the US, both compounding nominations were withdrawn; TB-500 is now covered by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), while thymosin alpha-1 is not covered. The draft is not an FDA approval and does not change either evidence grade. [1] [2] [4] [6] [8] [10] [12] [14] [17]
How do thymosin alpha-1 and TB-500 compare?
| Dimension | Thymosin alpha-1Favored | TB-500 |
|---|---|---|
| What it is [5] [9] [14] | A 28 amino acid N-acetylated thymic peptide (thymalfasin). | Synthetic 7 amino acid fragment (acetylated LKKTETQ) of thymosin beta-4, a 43 amino acid protein. FDA says thymosin beta-4 and TB-500 are not the same substance. |
| Note: The two are not related in structure or function; thymosin alpha-1 and thymosin beta-4, the protein TB-500 is a fragment of, were both first isolated from thymus extracts, which explains the shared name. | ||
| Mechanism [3] [5] [7] [9] [14] | Immune modulation through TLR2 and TLR9 on dendritic cells: more IL-2 and interferon, stronger natural killer and CD8 activity, fewer exhausted T cells. | Hypothesized, not shown, to share the actin binding role of thymosin beta-4. The mechanisms usually quoted were documented with full-length thymosin beta-4 in animals: it sequesters G-actin to regulate cell migration, promotes keratinocyte, endothelial, and cardiomyocyte migration, and activates Akt through a PINCH and ILK complex. |
| Evidence grade [1] [2] [6] [7] [14] [15] [16] | Human RCT: hepatitis B trial (98 patients, 40.6% versus 9.4% virological response) and sepsis trial (361 patients, 26.0% versus 35.0% 28 day mortality, p = 0.062). | Animal only: the studies of TB-500 itself tracked how it is broken down in horses and rats, and no study has given it to humans. The well-known results (rat wound reepithelialization up 42% at day 4 and 61% at day 7; improved cardiac function after infarction in mice) used full-length thymosin beta-4, and TB-500 has not been tested that way. |
| Main uses [4] [8] [14] | Chronic viral hepatitis, sepsis, vaccine adjuvant in immunocompromised patients, and cancer immunotherapy. | Marketed for tendon, muscle, and soft tissue recovery, with no study of TB-500 for any of them. The 72 patient dry eye trial that missed its primary endpoints tested eye drops of full-length thymosin beta-4. |
| Safety [1] [2] [9] [14] | Mostly injection site redness and transient aches; no serious drug related events in the sepsis trial. | No human safety data and no animal toxicity studies for TB-500; a theoretical concern about supporting tumor growth is carried over from thymosin beta-4, which drives cell migration and angiogenesis. |
| US compounding status [10] [11] [12] [17] [18] | Placed in 503A Category 2 in 2023; FDA now lists the nomination as withdrawn, so it is not on the bulks list, is not covered by HHS's October 2026 draft policy, and has no federal basis to be compounded. | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). |
| WADA status [13] | Unclear; not named on the list. | Prohibited at all times under S2, which names thymosin beta-4 and TB-500. |
| Dosing reference [1] [2] [8] [14] | Trials used 1.6 mg subcutaneously twice weekly for 6 to 12 months (hepatitis B) or twice daily for 7 days (sepsis). | Not established: no human study of TB-500 exists. The 28 day eye drop regimen in the dry eye trial was for full-length thymosin beta-4. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Thymosin alpha-1 | TB-500 |
|---|---|---|
| Class | 28 amino acid N-acetylated thymic peptide (synthetic form of a natural thymus derived immunomodulator) | Synthetic N-acetylated 7 amino acid fragment (amino acids 17 to 23, LKKTETQ) of thymosin beta-4, a 43 amino acid actin sequestering protein |
| What it is | Immune modulating thymus peptide approved abroad (not the US) for hepatitis B and as a vaccine booster; mixed sepsis trials; FDA nomination withdrawn. | Synthetic 7 amino acid fragment of thymosin beta-4. No human study of TB-500 itself; the human trials used the full-length protein. WADA banned. |
| Evidence | Evidence: Human RCT evidence | Evidence: Animal-only evidence |
| FDA status | Regulatory: Nomination withdrawn | Regulatory: HHS interim policy (draft) |
| Compounding | Not FDA approved, although approved as Zadaxin (thymalfasin) in more than 30 countries. FDA placed thymosin alpha-1 in 503A Category 2 in 2023, citing immunogenicity risk and inadequate safety information for compounded product. FDA's Category 2 page (current as of April 22, 2026) now lists it under bulk drug substances nominated but withdrawn, so it is no longer in Category 2 but has no active nomination and is not on the 503A bulks list. That leaves US compounding pharmacies without a lawful basis to make it. It was not among the peptides reviewed by the advisory committee in July 2026. | TB-500 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA's withdrawn list names it Thymosin beta-4, fragment (LKKTETQ). FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026 for wound healing: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds TB-500 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add TB-500 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. |
| WADA | WADA: WADA status unclear | WADA: WADA prohibited |
| Routes | Subcutaneous injection (all trials and foreign labeling) | Subcutaneous or intramuscular injection (as sold, and the routes FDA evaluated), Subcutaneous injection in horses and intraperitoneal injection in rats (TB-500 metabolism studies), Intravenous infusion, topical application, and eye drops (human trials of full-length thymosin beta-4, not TB-500) |
| Typical cost | Not available through licensed US channels since the 2023 Category 2 placement. Zadaxin is sold by prescription in countries where it is approved. | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient TB-500 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has thymosin alpha-1 been tested directly against TB-500?
No published trial has compared thymosin alpha-1 and TB-500 directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do thymosin alpha-1 and TB-500 cost?
| Dimension | Thymosin alpha-1 | TB-500 |
|---|---|---|
| Typical cost | Not available through licensed US channels since the 2023 Category 2 placement. Zadaxin is sold by prescription in countries where it is approved. | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient TB-500 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. |
| Price detail | Thymosin alpha-1 price by channel | TB-500 price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Thymosin alpha-1 page and the TB-500 page.
Frequently asked questions
Are thymosin alpha-1 and TB-500 the same thing?
No. Thymosin alpha-1 is a 28 amino acid immune modulator. TB-500 is a synthetic 7 amino acid fragment of thymosin beta-4, an actin binding protein involved in cell migration and tissue repair, and FDA says TB-500 and thymosin beta-4 are not the same substance. The names overlap because thymosin alpha-1 and thymosin beta-4 were both first found in thymus extracts. [5] [9] [14]
Which has better human evidence?
Thymosin alpha-1, which has randomized trials in hepatitis B and severe sepsis and is approved as Zadaxin abroad. TB-500 has no human study at all; the randomized eye drop trial in dry eye, where the primary endpoints were not met, tested full-length thymosin beta-4, which FDA says is not the same substance. [1] [2] [8] [14]
Is TB-500 proven to heal injuries?
Not in humans, and not in animals either. The rodent studies showing faster wound closure and improved heart repair used full-length thymosin beta-4, not TB-500, and FDA found no animal study testing whether TB-500 heals wounds. No human trial has tested TB-500 for tendon, muscle, or other musculoskeletal injuries. [6] [7] [8] [14]
Which can a US pharmacy compound?
TB-500 possibly, under conditions; thymosin alpha-1, no. Neither is on the 503A bulks list. TB-500 is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Thymosin alpha-1 is not covered: its nomination is listed as withdrawn, leaving no federal basis to compound it. State law still applies. [10] [11] [12] [17] [18]
Can athletes use them?
TB-500 is prohibited at all times under WADA section S2, which names thymosin beta-4. Thymosin alpha-1 is not named, so its status is unclear and athletes should check with their anti-doping organization. [13]
Conditions studied
From the blog
- TB-500 side effects and benefits: what the evidence shows
No human study of TB-500 has been published, so its side effects in people are unknown. What FDA's 2026 review found, which studies tested a different peptide, and its legal status.
- Thymosin alpha-1 benefits and side effects: the evidence
What randomized trials of thymosin alpha-1 showed in hepatitis B, sepsis, COVID-19, and vaccine response, which side effects they recorded, and where wellness claims outrun the data.
- TB-500 vs thymosin beta-4: is it the same peptide?
FDA says TB-500 and thymosin beta-4 are not the same substance. What each one is, which one the human and animal studies used, capsules and sprays, and the cancer question.
- Thymosin alpha-1 access: approved abroad, not in the US
Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and it is not on the 503A bulks list. What that means for access, forms, and thymalin.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Chien RN et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998PubMed 9581695, 1998
- [2]Wu J et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013PubMed 23327199, 2013
- [3]Liu Y et al. Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis 2020PubMed 32442287, 2020
- [4]Camerini R, Garaci E. Historical review of thymosin alpha 1 in infectious diseases. Expert Opin Biol Ther 2015PubMed 26098768, 2015
- [5]Dominari A et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol 2020PubMed 33362999, 2020
- [6]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
- [7]Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004PubMed 15565145, 2004
- [8]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
- [9]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
- [10]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Thymosin alpha-1 vs TB-500: evidence, cost, and legality. https://peptideagent.ai/compare/thymosin-alpha-1-vs-tb-500- HTML link
<a href="https://peptideagent.ai/compare/thymosin-alpha-1-vs-tb-500">Thymosin alpha-1 vs TB-500: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.